

Orbifloxacin Solid Formulation

Version 6.0 Revision Date: 2023/09/30 SDS Number: 801084-00017 Date of last issue: 2023/04/04
Date of first issue: 2016/07/15

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Orbifloxacin Solid Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.
Menuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION**GHS classification of chemical product**

Reproductive toxicity : Category 2

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Orbifloxacin Solid Formulation

Version 6.0	Revision Date: 2023/09/30	SDS Number: 801084-00017	Date of last issue: 2023/04/04 Date of first issue: 2016/07/15
----------------	------------------------------	-----------------------------	---

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and out-
lines of the emergency as-
sumed : Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of
the skin.
May form explosive dust-air mixture during processing, han-
dling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Orbifloxacin	113617-63-3	$\geq 3 - < 10$	
Magnesium stearate	557-04-0	$\geq 1 - < 10$	2-611

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-
vice immediately.
When symptoms persist or in all cases of doubt seek medical
advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty
of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms
and effects, both acute and
delayed : Suspected of damaging the unborn child.
Contact with dust can cause mechanical irritation or drying of
the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

Notes to physician : and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Orbifloxacin Solid Formulation

Version 6.0	Revision Date: 2023/09/30	SDS Number: 801084-00017	Date of last issue: 2023/04/04 Date of first issue: 2016/07/15
----------------	------------------------------	-----------------------------	---

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Storage

- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
- Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type	Control parame-	Basis
------------	---------	------------	-----------------	-------

Orbifloxacin Solid Formulation

Version 6.0 Revision Date: 2023/09/30 SDS Number: 801084-00017 Date of last issue: 2023/04/04
 Date of first issue: 2016/07/15

		(Form of exposure)	ters / Reference concentration / Permissible concentration	
Orbifloxacin	113617-63-3	TWA	0.2 mg/m ³ (OEB 2)	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection

: Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

: Work uniform or laboratory coat.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

dling or other means.

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Upper explosion limit / Up- : No data available
per flammability limit

Lower explosion limit / Lower explosion limit / : No data available
Lower flammability limit

Flash point : Not applicable

Decomposition temperature : No data available

pH : No data available

Evaporation rate : No data available

Auto-ignition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n- Partition coefficient: n- : No data available
octanol/water

Vapour pressure : No data available

Density and / or relative density

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

10. STABILITY AND REACTIVITY

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity

Not classified based on available information.

Components:**Orbifloxacin:**

Acute oral toxicity	:	LD50 (Rat): > 3,000 mg/kg Remarks: No mortality observed at this dose.
		LD50 (Mouse): > 2,000 mg/kg Remarks: No mortality observed at this dose.
		LD50 (Dog): > 600 mg/kg Symptoms: Vomiting Remarks: No mortality observed at this dose.
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 200 mg/kg Application Route: Intramuscular
		LD50 (Mouse): 500 mg/kg Application Route: Intramuscular
		LD50 (Rat): 233 mg/kg Application Route: Intravenous
		LD50 (Mouse): 250 mg/kg Application Route: Intravenous

Magnesium stearate:

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Orbifloxacin:**

Species	:	Rabbit
Method	:	Draize Test
Result	:	No skin irritation

Magnesium stearate:

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Orbifloxacin:**

Species	:	Rabbit
Result	:	Mild eye irritation
Method	:	Draize Test

Magnesium stearate:

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

Components:**Orbifloxacin:**

Test Type	: Maximisation Test
Exposure routes	: Dermal
Species	: Guinea pig
Result	: Not a skin sensitizer.

Magnesium stearate:

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Orbifloxacin:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal
	Test Type: Mouse Lymphoma Result: positive
	Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative
	Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
	: Weight of evidence does not support classification as a germ cell mutagen.
Germ cell mutagenicity - Assessment	

Magnesium stearate:

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials
-----------------------	--

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Orbifloxacin:**

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Orbifloxacin:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body weight Result: No adverse effects
----------------------	--

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses
-------------------------------	---

Test Type: Embryo-foetal development
 Species: Rabbit

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

	Application Route: Oral
	General Toxicity Maternal: NOAEL: 20 mg/kg body weight
	Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight
	Result: No effects on early embryonic development, Embryo-toxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain
	Test Type: Development
	Species: Dog
	Application Route: Oral
	Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
	Result: Effects on postnatal development, Skeletal malformations
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility	: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
	Species: Rat
	Application Route: Ingestion
	Method: OECD Test Guideline 422
	Result: negative
	Remarks: Based on data from similar materials
Effects on foetal development	: Test Type: Embryo-foetal development
	Species: Rat
	Application Route: Ingestion
	Result: negative
	Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****Orbifloxacin:**

Species	: Rat
NOAEL	: 20 mg/kg
LOAEL	: 80 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Testis, Liver, Kidney, spleen

Species	: Mouse
---------	---------

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

NOAEL	: 80 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Species	: Juvenile dog
NOAEL	: 50 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 14 Days
Target Organs	: Heart, Bone
Symptoms	: Gastrointestinal disturbance
Remarks	: mortality observed

Species	: Juvenile dog
NOAEL	: 2 mg/kg
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 90 Days
Target Organs	: Bone
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 37.5 mg/kg
Application Route	: Oral
Exposure time	: 30 Days

Species	: Cat
NOAEL	: 7.5 mg/kg
LOAEL	: 22.5 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Symptoms	: Gastrointestinal disturbance

Magnesium stearate:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Orbifloxacin:**

Ingestion	: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitisation.
-----------	--

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

II

12. ECOLOGICAL INFORMATION

Ecotoxicity**Components:****Magnesium stearate:**

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability**Components:****Magnesium stearate:**

Biodegradability	:	Result: Not biodegradable Remarks: Based on data from similar materials
------------------	---	--

Orbifloxacin Solid Formulation

Version 6.0 Revision Date: 2023/09/30 SDS Number: 801084-00017 Date of last issue: 2023/04/04
Date of first issue: 2016/07/15

Bioaccumulative potential**Components:****Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION**Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law**Harmful Substances Prohibited from Manufacture**

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Article 57-2 (Enforcement Order Table 9)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	>=1 - <10	-

Substances Subject to be Indicated Names

Article 57 (Enforcement Order Article 18)

Chemical name	Remarks
---------------	---------

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

Magnesium stearate	-
--------------------	---

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

|| Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION**Further information**Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-

Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
6.0	2023/09/30	801084-00017	Date of first issue: 2016/07/15

recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN